A Phase 1 Study to Evaluate Safety, Tolerability, and PK of TBI-223 in Healthy Adults

A Phase 1 Study to Evaluate Safety, Tolerability, and PK of TBI-223 in Healthy Adults

Conditions:   Tuberculosis;   Tuberculosis, Pulmonary
Interventions:   Drug: TBI-223 50mg;   Drug: Placebo for TBI-223 50mg;   Drug: TBI-223 100, 300, 600, 1200, 1400 mg;   Drug: Placebo for TBI-223 100, 300, 600, 1200, 1400 mg
Sponsor:   Global Alliance for TB Drug Development
Recruiting
ClinicalTrials.gov: Infections_Infectious_Diseases | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

February 22, 2019 / by / in
Comments